Transparency

Medicare numbers trigger physician anger

Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.

Sunshine data highlights major billers

Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.

Industry mutes doctors

ProPublica says drugmakers have slashed speakers' budgets.

Industry wants EMA to open its books

Industry associations want to see how money for review applications is spent.

Novartis enhances data access

The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Janssen signs onto Yale data-sharing project

The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.

Companies view Sunshine differently

Companies view Sunshine differently

By

A report indicates pharma companies do not agree on what research needs to be reported.

Europe may delay transparency

The EMA is wading through thousands of comments and may push back its clinical trial transparency initiative.

Many unclear on 2013 Sunshine data

Many unclear on 2013 Sunshine data

By

A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

Good day, Sunshine: Tools help docs track payments

Good day, Sunshine: Tools help docs track payments

By

With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.

The complexity of cracking open the data door

The complexity of cracking open the data door

By

Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.

Business briefs: GSK, UCB, AZ, Biogen Idec, CVS, Roche, Forest

China's industry investigation widens beyond GlaxoSmithKline; PhRMA's European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient's death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.

Industry pushing for further clarity on Sunshine Act

Industry pushing for further clarity on Sunshine Act

By

With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.

Business briefs: GSK and Sanofi, plus state legislative news

GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.

Novartis: lawsuits, layoffs and, by the way, earnings

By

It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.

Business Briefs: GSK, Astellas, Vertex and Orexigen

GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.

Business briefs: Reps mum on adverse events; FCC's new mHealth director; med schools tighten speaking limits

A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation

Business briefs: AstraZeneca, Everyday Health, J&J

AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales

CMS releases "Sunshine" final rule: federal preemption, August start date

CMS releases "Sunshine" final rule: federal preemption, August start date

By

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.

Researcher takes aim at clashing drug data

By

An expert witness in a 2008 lawsuit highlights holes in clinical data, and finds that corporate and published trial data do not necessarily correspond.

Business briefs: Abbott, Sunshine, Allergan and Watson

Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.

Company news: Edelman, CMS, McKesson

Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.

BMJ will require authors to disclose clinical trial data

By

Starting next year, the BMJ will not publish academic papers on drugs or devices unless the relevant anonymized patient-level data are made available for third-party study.

Sunshine Act could scare docs away from commercially-supported CME

Sunshine Act could scare docs away from commercially-supported CME

By

Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.

Grassley blasts CMS foot-dragging on Sunshine Act

Grassley blasts CMS foot-dragging on Sunshine Act

By

The Centers for Medicare and Medicaid Services, now a month overdue to issue draft guidelines for reporting pharma-physician contacts as required under healthcare reform legislation, said the department is working on it, but offered nothing in the way of a timeline.

Piercing the veil, but missing the value of medicine's industry ties

By

ProPublica's Dollars for Docs database has grown richer in pharma company payments but falls short in putting context around those expenditures, say industry-side critics.

GSK paid $57 mil. to doctors for speaking and advising in '10

By

GlaxoSmithKline said Thursday that it paid more than 5,000 US healthcare professionals a total of $56.8 million last year for promotional talks or serving on advisory boards.

Email Newsletters